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Aluminum (Al), which is omnipresent in human life, is a potent neurotoxin. Here, we have tested the 
potential for egg White Hydrolysate (eWH) to protect against changes in cognitive function in rats 
exposed to both high and low levels of Al. Indeed, EWH has been previously shown to improve the 
negative effects induced by chronic exposure to heavy metals. Male Wistar rats received orally: Group 
1) Low aluminum level (AlCl3 at a dose of 8.3 mg/kg b.w. during 60 days) with or without EWH treatment 
(1 g/kg/day); Group 2) High aluminum level (AlCl3 at a dose of 100 mg/kg b.w. during 42 days) with or 
without EWH treatment (1 g/kg/day). After 60 or 42 days of exposure, rats exposed to Al and EWH did 
not show memory or cognitive dysfunction as was observed in Al-treated animals. Indeed, co-treatment 
with EWH prevented catalepsy, hippocampal oxidative stress, cholinergic dysfunction and increased 
number of activated microglia and COX-2-positive cells induced by Al exposure. Altogether, since 
hippocampal inflammation and oxidative damage were partially prevented by EWH, our results suggest 
that it could be used as a protective agent against the detrimental effects of long term exposure to Al.
Aluminum (Al) is omnipresent in modern life without any known biological beneficial effect1. The human body 
burden of Al increases every single day due to numerous anthropogenic and natural sources of Al2,3. Therefore, 
the Provisional Tolerable Weekly Intake4,5 of Al for humans (1 mg Al/kg body weight -b.w.) is exceeded for a 
significant part of the world population6,7. The consequences of the enhanced human body burden of Al are not 
entirely clear2, but may have implications for human disease including neurological disorders such as Alzheimer’s 
disease (AD)8–10, cardiovascular disease11,12 and reproductive dysfunction13,14.
Al is a widespread neurotoxin associated with cognitive and motor impairments, mostly related with neurode-
generative diseases15,16. For many years Al has been implicated in the etiology of AD in the so-called “aluminum 
hypothesis in AD” and now the most recent research has described how it is involved in the onset, progression 
and aggressive nature of AD8,10. However, while a role for Al in AD is now more certain we still do not understand 
the predominant toxic mechanism. The toxicity of Al has been related to its pro-oxidant activity, acting through 
the formation of an Al-superoxide radical cation17 capable of reducing Fe(III) to Fe(II) inducing the Fenton 
reaction18.
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Due to unanswered questions regarding the human body burden of Al and its real consequences, there is an 
urgent need for prevention and therapy and, preferably without considerable adverse effects such as disrupt-
ing essential metals. In this sense, Egg White Hydrolysate (EWH) bioactive peptides, obtained after enzymatic 
hydrolysis with pepsin19, could be beneficial to counteract the negative effects of Al in human disease. Previously, 
we have demonstrated the ability of EWH to counteract health effects induced by different conditions such as 
cardiometabolic dysfunction and heavy metal exposure19–22. The protective effects of EWH seem to be related to 
its antioxidant and anti-inflammatory properties22–24.
The behavioral effects of Al exposure on experimental rodents have been studied and, at high levels, Al has 
been used as an animal model of AD25–27. Al-exposed rats at 100 mg Al/kg/day, develop progressive deterioration 
of spatial memory26,27 and, at 250 mg/kg object recognition memory and sociability were impaired in Al-treated 
mice28. Social interaction impairment was also shown following injection of Al adjuvants in neonatal mice pups 
during the early period of postnatal development29. Recently, we have demonstrated that Al exposure at a level 
which might be considered equivalent to normal dietary intake was sufficient to promote cognitive dysfunc-
tion, such as memory impairment and that these effects were almost the same when we treated rats at a higher 
(super-dietary level) dose of Al30. Herein, we have investigated if EWH is effective in protecting against cognitive 
function in rats exposed to both a low and high level of dietary Al.
Methods
Preparation of EWH. EWH was prepared by pepsin hydrolysis of crude egg white, as previously described20. 
Briefly, commercial pasteurized egg white was hydrolyzed with BC Pepsin 1:3000 (E.C. 3.4.23.1; from pork stom-
ach, E:S: 2:100 w-w, pH 2.0, 38 °C), purchased from Biocatalysts (Cardiff, United Kingdom), for 8 h. Enzyme 
inactivation was achieved by increasing the pH to 7.0 with 5 N NaOH. The hydrolysate was centrifuged at 2500 g 
for 15 min. and the supernatants were frozen and lyophilized. The principal components of EWH after pep-
sin digestion for 8 h were previously determined by reverse-phase liquid chromatography–mass spectrometry 
(RP-HPLC-MS/MS), peptides: FRADHPFL, RADHPFL, YAEERYPIL, YRGGLEPINF, ESIINF, RDILNQ, IVF, 
YQIGL, SALAM, FSL19,31.
Animals. Male Wistar rats (90 days-old, 360 ± 11.2 g) were obtained from the Charles River Animal 
Laboratory, Barcelona, Spain. Animals were housed at standard conditions (constant room temperature, humid-
ity, and 12:12 h light-dark) with water and fed ad libitum. All experimental protocol were performed in accordance 
with the guidelines stated by the Brazilian Societies of Experimental Biology and the European and Spanish legis-
lation on care and use of experimental animals (EU Directive 2010/63/EU for animal experiments; R.D. 53/2013). 
The experimental protocol was approved by the Ethics Committees on Animal Use at both Universidade Federal 
do Pampa, Uruguaiana, Rio Grande do Sul, Brazil (Process Number: 028/2014) and Universidad Rey Juan Carlos, 
Madrid, Spain (Process Number: 39/2012).
Male Wistar rats were randomly distributed into two main groups according to their Al exposure and received 
orally and once a day: Group (1) Low aluminum level - rats were divided into 4 subgroups (N = 8) (1a-d) and 
received for 60 days: (a) Control - ultrapure water as the drinking water (Milli-Q, Merck Millipore Corporation. 
© 2012 EMD Millipore, Billerica, MA); (b) AlCl3 at a dose of 8.3 mg/kg b.w. in the drinking water, representing 
human Al exposure by diet30; (c) EWH - ultrapure water as the drinking water and EWH at 1 g/kg/day by gav-
age32; (d)EWH + AlCl3 at 8.3 mg/kg bw; and Group (2) High aluminum level - rats were divided into 4 subgroups 
(N = 8/each) (2a-d) and received for 42 days: (a) Control – ultrapure water by oral gavage; (b) AlCl3 at 100 mg/kg 
b.w. for by gavage, representing a high level of human exposure to Al26; (c) EWH - ultrapure water and EWH at 
1 g/kg/day both by gavage32; (d) EWH + AlCl3 at 100 mg/kg b.w.
Rat body weights, food and water or Al intakes for groups that have received Al in the drinking water (Group 
1) were measured once a week. After 60 (Group 1a-d) or 42 (Group 2a-d) days of treatment the animals were 
submitted to behavioral tests: 1° day: open field, plus maze and hot plate (control behavioral experiments); 2°–6° 
day: object recognition tests (short and long-term memory). After the exposure period and tests, rats were euth-
anized and the bilateral hippocampus was quickly dissected out and, one side was processed for histological and/
or immunohistochemical studies and the other side was quickly homogenized in 50 mM Tris HCl, pH 7.4, (1/10, 
w/v), centrifuged (2400 g, 10 min, 4 °C) and frozen at −80 °C for further biochemical determinations.
AlCl3.6 H2O solution was prepared in ultrapure water being the concentration of each stock solution of 
0.034 M (Group 1; 8.3 mg/kg/b.w.) and 0.331 M (Group 2; 100 mg/kg/b.w.). All reagents and salts were obtained 
from Sigma-Aldrich and Merck (Darmstadt, Germany).
Control behavior tests. Control behavior tests were performed to guarantee that the procedures adopted 
in the experiment’s design did not alter rats’ locomotion and exploration, anxiety state and pain threshold, since 
these alterations could interfere on memory testing. After testing, the results were compared between groups. 
To evaluate locomotion and exploration the Open Field test was used; the number of crossing and rearings were 
monitored by 5 min as described previously33. The Elevated Plus Maze test was used to evaluate the anxiety behav-
ior; each rat was placed in the maze for 5 min and the time in the open arms of the maze was monitored for each 
rat as previously described34. The hot plate test was used to evaluate the pain threshold; the animals’ time to react 
was measured as previously described35, considering a ceiling of 45 s, to avoid lesions.
Short and long-term object recognition memory. Object recognition memory test (OR) was used to 
evaluate the short (STM) and the long-term memory (LTM) of the animals. After the treatments were ended, the 
OR protocol was started. It was performed in an apparatus (50 cm × 50 cm × 50 cm area built with plastic, ply-
wood and transparent acrylic, as previously described36). Initially, the animals were habituated to the arena, being 
placed in it for 20 min per day during 4 consecutive days. In the fifth day, the OR training was performed; for this, 
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two different objects (a and b) were placed in the apparatus and the rat had 5 minutes to free exploration. The 
objects were made of different materials, and the exploration was monitored considering sniffing or touching the 
objects with the nose and/or forepaws by a video camera. STM test was performed 3 h after training, when one of 
the objects was changed by a new one (c). LTM test was performed 24 h after training, when one of the objects was 
changed by a new one (d). In each test session, the rat had 5 minutes to freely exploration of the objects. Between 
each animal’s training or testing session, the arena and the objects were cleaned with 70% ethanol to avoid influ-
ences of olfactory stimuli in the results. In each OR session the exploration time of each one of the objects was 
recorded for further analysis.
Catalepsy. Catalepsy was measured using a modification of the “ring test”37. Rats were hung by their front 
paws from a rubber-coated metal ring fixed horizontally at a height that allowed their hind paws to just touch the 
bench. The time taken for the rat to move-off the ring was measured with a cut-off limit of 30 seconds.
Reactive oxygen species levels. Levels of reactive oxygen species in the hippocampus were determined by 
the spectrofluorometric method described by Loetchutinat et al.38 with previous modifications30. The ROS levels 
were expressed as fluorescence units.
Lipid peroxidation. Lipid peroxidation was measured in the hippocampal tissue as malondialdehyde 
(MDA) using a colorimetric method, as previously described by Ohkawa et al.39, with modifications30. The results 
were expressed as nanomoles of MDA per mg of protein.
Ferric Reducing/Antioxidant Power (FRAP) Assay. The total antioxidant capacity in the hippocampal 
tissue was measured by FRAP assay40, with modifications30. Results are presented with particular reference to 
Trolox equivalents.
Acetylcholinesterase (AChE) activity. The AChE activity in hippocampal tissue was assessed by the 
Ellman method41, with modifications30. Results were expressed as micromoles of acetylthiocholine iodide hydro-
lyzed/min/mg of protein. Proteins were measured according to Bradford42 using bovine serum albumin as a 
standard.
Histology analysis. To carry out the histological studies hippocampal tissue was fixed in 10% formaldehyde 
for 1–2 days. After several intensive washings, tissues were embedded in paraffin, sectioned at 5 µm and stained 
with hematoxylin/eosin. For the histological study, 10 randomly chosen regions of each hippocampus were ana-
lysed as a blinded evaluation, and, studied under a Zeiss Axioskop 2 microscope (Zeiss, Jena, Germany) equipped 
with the image analysis software package AxioVision 4.6. The analysis was made under the 10X objective.
Immunohistochemistry. Hippocampus immunohistochemistry was performed on paraffin-embedded 
sections of 5 µm thickness. De-paraffined slides were washed with phosphate buffered saline (PBS) with 0.05% 
Tween 20 (Calbiochem, Darmstadt, Germany). Thereafter sections were incubated for 10 min in 3% (v/v) hydro-
gen peroxide to inhibit endogenous peroxidase activity and blocked with fetal bovine serum for 30 minutes to 
minimize nonspecific binding of the primary antibody. Sections were then incubated overnight at 4 °C with a 
rabbit polyclonal antibody against microglia (anti-Iba 1, 1:500, Wako Chemicals, USA, Inc) to quantify the num-
ber of activated microglia, which is consistent with the presence of inflammation. Sections were also incubated 
with the primary rabbit polyclonal antibody against cyclooxygenase- 2 (COX-2, 1:75, Santa Cruz Biotechnology, 
Inc.). After incubation, samples were washed with PBS-Tween. The peroxidase-based kit Masvision (Master 
Diagnostica, Granada, Spain) was used as secondary antibody. Samples were counterstained with hematoxylin 
and coverslips were mounted with Eukitt (O. Kindler GmbH & Co, Freiburg, Germany). To determine the level 
of non-specific staining the preparations were incubated without the primary antibody. COX-2 immunohisto-
chemistry was evaluated for intensity of immunoreactivity on a 0 to 4+ scale. The overall intensity of the staining 
reaction was scored with 0 indicating no immunoreactivity and no positive cells, 1+ weak immunoreactivity and 
<10% of positive cells, 2+ mild immunoreactivity and 10–30% of positive cells, 3+ moderate immunoreactivity 
and 31–60% of positive cells, and 4+ strong immunoreactivity and 61–100% of positive cells, as described by 
Kohno et al.43.
Lumogallion staining for presence of aluminum. Lumogallion staining was performed on 
formalin-fixed hippocampal tissue using a recently validated method to identify the presence of Al in tissues44,45. 
Briefly, re-hydrated tissues sections were immediately placed into either 1 mM lumogallion (TCI Europe N.V. 
Belgium) buffered in 50 mM PIPES, pH 7.4 or the PIPES-buffer alone for auto-fluorescence analyses for 45 min-
utes. Slides were carefully washed 6 times with PIPES-buffer and rinsed in ultrapure water for 30 seconds. Sections 
were then incubated with DAPI to identify the cell nucleus (4′,6-Diamidino-2-phenylindole dihydrochloride - 
DAPI, 1:10.000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Afterwards, slides were mounted using 
an aqueous mounting medium and stored horizontally at 4 °C overnight prior to imaging. Sections of tissues were 
imaged using a Zeiss Axioskop 2 microscope (Zeiss, Jena, Germany).
Statistical analysis. Results are expressed as mean ± SD. The time spent exploring each of the objects in the 
OR test was converted to a percentage of total exploration time; the analysis were made using a one-sample t-test 
considering a theoretical mean of 50%. The other results were analyzed using one or two way ANOVA followed 
by Bonferroni post hoc test when necessary. Values of P < 0.05 were considered significant.
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Results
Body weight, fluid and feed intakes. The liquid, feed intakes and body weights of rats were not dif-
ferent between groups at the beginning or end of the treatments (body weight varying from 284.4 ± 12.5 to 
468.1 ± 10.5 g - Table 1).
Control behavioral testing, STM and LTM results. For group 1 or group 2, Al exposure, the EWH treat-
ment alone or co-treated with Al had no effect in the quantity of crossings and rearings during the open field test 
(Table 2 – Open field). In the same manner, neither of the treatments affected the permanency of the animals in 
the open arms during the plus maze test (Table 2 – Plus maze) or in latency time to reaction during the hot plate 
section (Table 2 – Hot plate).
During OR training, all rats in both groups spent about 50% of the total exploration time to explore two 
new objects (a and b) (Group 1: Fig. 1A,B: Cont t(9) = 0.12; P = 0.90, EWH: t(9) = 1.85; P = 0.09; AlCl3 (Al) 8.3: 
t(8) = 0.14; P = 0.88; Al 8.3 + EWH: t(9) = 1.88; P = 0.09; Group 2: 1B, 1 C, 1D: Cont t(7) = 0.44; P = 0.67; EWH: 
t(9) = 0.77; P = 0.45; Al 100: t(9) = 0.62; P = 0.55; Al 100 + EWH: t(9) = 1.51; P = 0.16), as expected.
However, 3 h after training, in the short-term memory testing sessions, while control (Ct) animals explored the 
new object more often than the familiar object (Fig. 1A test Cont t(9) = 2.51, P = 0.03; Fig. 1B test Cont t(7) = 2.60, 
P = 0.03), Al-treated rats (Group 1b and Group 2b) spent a similar time exploring these objects, approximately 
50% of the total time (Fig. 1A test Al t(8) = 1.58, P = 0.15; Fig. 1B test t(9) = 0.20, P = 0.84). EWH had no effect per 
se (Fig. 1A test EWH t(9) = 3.53, P = 0.06; Fig. 1B test t(9) = 9.73, P < 0.0001) while, when rats were treated with Al 
and EWH (Group 1d and Group 2d), they explored the novel object (c) for a significantly longer period of time 
(more than 50%Fig. 1A test Al + EWH t(9) = 7.15, P < 0.0009; Fig. 1B test t(9) = 6.25, P = 0.0001), similar to their 
respective control groups (Group 1a and Group 2a).
We made similar observations in the 24 h test (long - term memory testing sessions). The Al-treated rats 
(Group 1b and Group 2b) explored both objects for approximately the same amount of time, without differences 
in the time spent exploring the familiar and the novel object (Fig. 1C test Al t(9) = 1.22, P = 0.25; Fig. 1D test 
t(9) = 1.82, P = 0.10). When rats were treated with Al and EWH (Group 1d and Group 2d), they spent more than 
50% of the total exploration time exploring the new object (c) (Fig. 1C test Al + EWH t(9) = 4.69, P = 0.001; Fig. 1D 
test t(9) = 11.25, P < 0.0001), similar to their respective control groups (Group 1a and Group 2a). However, 3 h or 
24 h after training, in the short and long term memory testing sessions, respectively, the Al-treated rats (Group 
1b and Group 2b) spent a similar time exploring the familiar and the novel object (a and c or d) (Fig. 1A–D – 
test session). While, when rats were treated with Al and EWH (Group 1d and Group 2d), they explored the novel 
object (c) for more than 50% of the time (Fig. 1A–D – test session), similar to their respective control groups 
(Group 1a and Group 2a).
In the catalepsy test, a main effect for the groups was observed on rats exposed to low levels of Al (Group 1b: 
F(3,84) = 3.577; P = 0.01; Fig. 2A) or high (Group 2b: F(3,84) = 3.421; P = 0.02; Fig. 2B). Additionally, a main effect of 
the time was observed on rats exposed to low levels of Al (Group 1b: F(2,84) = 10.19; P = 0.0001, Fig. 2A) or high 
(Group 2b: F(2,84) = 7.324; P = 0.001; Fig. 2B). Interaction effect was observed on rats exposed to low (Group 1b: 
F(6,84) = 3.134; P = 0.008; Fig. 2A), but not on rats treat with high levels of Al (Group 2b: F(6,84) = 1.629; P = 0.14; 
Fig. 2B).
Body weight Feed/fluid intakes
Al 8.3 mg/kg + EWH Al 100 mg/kg + EWH
Control EWH AlCl3 AlCl3 + EWH Control EWH AlCl3 AlCl3 + EWH
Initial body weight (g) 365.6 ± 20.4 385.6 ± 29.7 409.7 ± 28.4 397.7 ± 28.6 284.4 ± 29.3 297.1 ± 25.7 283.1 ± 29.6 309.5 ± 28.4
Final body weight (g) 434.1 ± 25.1 467.6 ± 29.1 468.1 ± 30.2 448.4 ± 22.9 386.9 ± 30.2 413.1 ± 30.6 408.3 ± 29.4 408.5 ± 25.5
Feed intakes (g) 21.4 ± 0.6 22.2 ± 1.5 22.5 ± 0.6 22.2 ± 1.3 20.7 ± 0.8 21.9 ± 1.6 21.4 ± 0.7 21.5 ± 0.5
Fluid intakes (mL) 36.1 ± 2.3 37.7 ± 2.5 36.1 ± 1.6 36.7 ± 0.9 31.4 ± 2.4 32.4 ± 2.8 31.7 ± 1.1 30.6 ± 0.8
Table 1. Body weights and dietary intakes in each of the treatment groups. Mean and SD are given for n = 8 
rats. P > 0.05 (ANOVA).
Behavioral tasks
Al 8.3 mg/kg + EWH Al 100 mg/kg + EWH
Control EWH AlCl3 AlCl3 + EWH
F(df); P 
value Control EWH AlCl3 AlCl3 + EWH
F(df); P 
value
Open Field Crossings (n) 44.33 ± 28.60 37.70 ± 13.31 41.60 ± 22.75 42.70 ± 15.03 F(3,35) = 0.82P = 0.48 41.44 ± 19.93 43.80 ± 21.63 53.10 ± 24.64 38.00 ± 22.90
F(3,35) = 1.36
P = 0.26
Rearings (n) 17.33 ± 9.97 7.70 ± 3.59 13.50 ± 10.72 14.80 ± 7.36 F(3,35) = 0.68P = 0.56 11.11 ± 5.96 15.60 ± 8.60 14.50 ± 8.84 12.50 ± 5.91
F(3,35) = 2.77
P = 0.09
Plus maze Time in open arms (s) 15.26 ± 23.06 16.89 ± 10.60 10.43 ± 12.37 19.54 ± 15.60
F(3,35) = 0.27
P = 0.84 20.88 ± 29.73 29.90 ± 13.57 24.08 ± 17.29 26.53 ± 26.06
F(3,34) = 0.47
P = 0.7
Hot plate Times (s) 13.63 ± 3.33 9.20 ± 4.94 11.50 ± 4.60 12.50 ± 4.35 F(3,35) = 1.09P = 0.36 12.11 ± 4.64 8.70 ± 4.90 9.40 ± 4.27 9.00 ± 4.34
F(3,34) = 0.43
P = 0.18
Table 2. Results of control behavioral testing performed by Open Field, Elevated Plus Maze and Hot Plate 
testing. Mean and SD are given for n = 8 rats. P > 0.05 (ANOVA).
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Figure 1. Effects of EWH on short and long-term recognition memory of rats exposure to aluminum. After AlCl3 
exposure for 60 (8.3 mg/kg bw per day – A,B) or 42 days (100 mg/kg bw per day – C,D), co-treated or not with 
EWH, object recognition task (OR) was used to evaluate memory. After training in the OR task, the rats’ short 
(STM) and long-term memory (LTM) are tested, considering test session performed 3 h and 24 h after OR training. 
During the training session the rats were exposed to two objects (“a” and “b”). In each test session one of the objects 
were replaced by a new one (“c”, in the STM test, or “d”, in the LTM test). Results are expressed as mean ± SD of the 
percentage of total exploration time. *P < 0.05 in one-sample t-test; theoretical mean of 50% (n = 8).
Figure 2. Effect of EWH on catalepsy development in Al-treated rats. The catalepsy analysis was performed before 
(day 0), in the middle (30 or 21 days) and end of the treatments (60 or 42 days) with AlCl3 for 60 (8.3 mg/kg bw  
per day – A) or 42 days (100 mg/kg bw per day – B), co-treated or not with EWH. Results are expressed as 
mean ± SD, n = 8, *P < 0.05 compared with their corresponding controls, #P < 0.05 compared with AlCl3 group 
(two-way ANOVA and Bonferroni as post-hoc test).
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Animals exposed to Al during long-term (Group 1b) showed increased latency time for reaction in the test 
when compared to their respective control group, being positive for catalepsy (P < 0.01; Fig. 2A). However, 
rats treated with low levels of Al and co-treated with EWH demonstrated a motor behavior different from Al 
non-treat animals and similar to the control and EWH rats (P > 0.05 for control vs. ACl3 + EWH; P < 0.01 for ACl3 
vs. AlCl3 + EWH; Fig. 2A).
Rats exposed to high levels of Al for 42 days (Group 2b) showed increased latency time for reaction in the 
test when compared to their respective control group, being positive for catalepsy (P < 0.01; Fig. 2B). However, 
rats treated with low levels of Al and also co-treated with EWH demonstrated a motor behavior different from 
Al non-treat animals and similar to the control and EWH rats (P > 0.05 for control vs. ACl3 + EWH; P < 0.05 for 
ACl3 vs. AlCl3 + EWH; Fig. 2B).
Oxidative stress and AChE activity. Al treatment at low (Group 1b) and high doses (Group 2b) raised the 
ROS and lipid peroxidation levels and, decreased the hippocampal antioxidant capacity (ROS Fig. 3A: Al 8.3 vs 
Ct P = 0.0014; Fig. 3B: Al 100 vs Ct P = 0.0026; Lipid peroxidation Fig. 3C: Al 8.3 vs Ct P = 0.0437; Fig. 3D: Al 100 
vs Ct P = 0.0013; Total antioxidant capacity Fig. 3E: Al 8.3 vs Ct P = 0.0264; Fig. 3F: Al 100 vs Ct P = 0.0010). Rats 
exposed to both Al and EWH (Group 1d and Group 2d) showed oxidative stress biomarkers similar to the levels 
found in the control and EWH rats (ROS Fig. 3A: Al 8.3 + EWH vs Al P = 0.0038; Fig. 3B: Al 100 + EWH vs Al 
Figure 3. Effect of EWH on oxidative stress assessments in Al-treated rats. Reactive oxygen species (ROS), lipid 
peroxidation and total antioxidant capacity (FRAP- Ferric Reducing/Antioxidant Power) levels in hippocampus 
of rats treated with AlCl3 for 60 (8.3 mg/kg bw per day – A,C,E) or 42 days (100 mg/kg bw per day – B,D,F), co-
treated or not with EWH. Results are expressed as mean ± SD, n = 8, *P < 0.05 compared with their corresponding 
controls, #P < 0.05 compared with AlCl3 group (two-way ANOVA and Bonferroni as post-hoc test).
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Figure 4. Effect of EWH on acetylcholinesterase (AChE) activity in Al-treated rats. Values of AChE activity on 
hippocampus of rats treated with AlCl3 for 60 (8.3 mg/kg bw per day – A) or 42 days (100 mg/kg bw per day – B),  
co-treated or not with EWH. Results are expressed as mean ± SD, n = 8, *P < 0.05 compared with their 
corresponding controls (two-way ANOVA and Bonferroni as post-hoc test).
Figure 5. Effect of EWH on hippocampus histopathology in Al-treated rats. Normal histoarchitecture in 
hippocampus of control (A) and EWH (B) groups. Tissues sections of Al-treated rats with 8.3 mg/kg b.w. (C) 
and with 100 mg/kg b.w. (E) Arrows indicate blood vessels in C and vacuolarized cells in E. The co-treatment 
with EWH ameliorates the damage after Al exposure with 8.3 mg/kg (D) and 100 mg/kg (F). Scale bar: 100 µm 
(objective X10).
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P = 0.0464; Lipid peroxidation Fig. 3C: Al 8.3 + EWH vs Al P = 0.0029; Fig. 3D: Al 100 + EWH vs Al P > 0.9999; 
Total antioxidant capacity Fig. 3F: Al 100 + EWH vs Al P = 0.0373).
Al-treated rats at low and high doses showed an inhibition of 42% (Group 1b) and 37% (Group 2b) on AChE activ-
ity, respectively (Fig. 4A: Al 8.3 vs Ct P = 0.0057; Fig. 4B: Al 100 vs Ct P = 0.0122). Al-exposed rats at 8.3 mg/kg (Group 
1a) and co-treated with EWH (Group 1d) showed an inhibition of 1.7% in the enzyme activity and, Al-exposed rats 
at100 mg/kg (Group 2b) and co-treated with EWH (Group 2d) showed a not statistical difference inhibition of 11.6% 
on AChE activity (Fig. 4A: Al 8.3 + EWH vs Al P = 0.0292; Fig. 4B; Al 100 + EWH vs Al P = 0.4228).
Histology and neuroinflammation analysis – microglia and COX-2. Histology showed normal his-
toarchitecture of the hippocampus in control (Group 1a and Group 2a) and EWH rats (Group 1c and Group 2c) 
(Fig. 5A,B). On the contrary, Al exposure at an equivalent human dietary level (Group 1b) and at a high level of 
human exposure (Group 2b) impaired the normal histoarchitecture of the hippocampus, these effects not being 
restricted to specific sub-regions of the hippocampus, but similar across the whole tissue. Specifically, Al at the 
lower dose (Group 1a) promoted alterations in vessel morphology and Al at 100 mg/kg (Group 2b) induced gran-
ulovacuolar structures in the cellular cytoplasm (Fig. 5C,E, respectively). Rats exposed to Al and EWH (Group 1d 
and Group 2d) showed histology similar to the control groups (Fig. 5D,F).
Al exposure to the low dose of 8.3 mg/kg for 60 days (Group 1b) and to the higher dose of 100 mg/kg for 
42 days (Group 2b) increased the number of activated microglia in hippocampus (Fig. 6B,E), being 3.4 and 
4.5 times higher, when compared with the respective control groups (Fig. 6G: Al 8.3 vs Ct P = 0.0053; Fig. 6H: 
Al 100 vs Ct P = 0.0023). Moreover, the overall score for COX-2 immunoreactivity in the hippocampal tissue 
was 3.4 in Al-treated rats at Group 1 and 3.8 for Group 2, significantly higher when compared with the control 
groups (2.0 and 2.2, for Group 1a and Group 2a, respectively) (Fig. 7B,E,G: Al 8.3 vs Ct P = 0.0261; 7 H: Al 100 
vs Ct P = 0.0018). Al-treated rats and co-treated with EWH (Group 1d and Group 2d) showed number of acti-
vated microglia similar to control-rats (Fig. 6C,F,G: Al 8.3 + EWH vs Al P = 0.0201; 6 H: Al 100 + EWH vs Al 
P = 0.0302) and weakly positive immunoreactivity for COX-2 in the group 1d, treated with Al at the lowest dose 
(Fig. 7C,F,G: Al 8.3 + EWH vs Al P = 0.0201; 7 H: Al 100 + EWH vs Al P = 0.634).
Figure 6. Effect of EWH on hippocampus microglia in Al-treated rats. Activated microglia (arrows) in 
hippocampus of controls group (A,D), Al at 8.3 mg/kg b.w. (B) and Al at 100 mg/kg b.w. (E), EWH + Al 8.3 (C) 
and EWH + Al 100 (F) detected with the Iba-1 antibody. Scale bar 50 µm. Average numbers of activate microglia 
per field (objective X40) of rats treated with AlCl3 at 8.3 (G) or 100 (H), co-treated or not with EWH. Results are 
expressed as mean ± SD, n = 8, *P < 0.05 compared with their corresponding controls (two-way ANOVA and 
Bonferroni as post-hoc test).
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Presence of aluminum in the hippocampus. The presence of Al in the hippocampus was confirmed 
using lumogallion and fluorescence microscopy. The tissue showed green autofluorescence in the absence of 
lumogallion (supplementary information, Fig. SIA) and no specific fluorescence in the control (Group 1a and 
Group 2a) and EWH rats (Group 1c and Group 2c) (supplementary information, Fig. SIB & SIC). Lumogallion 
fluorescence identified Al in the hippocampus of Al-treated rats as evidenced by bright orange fluorescence 
(Fig. 8A,C), using lumogallion fluorescence, DAPI- fluorescence and lumogallion & DAPI overlay. Rats in the 
Al + EWH groups (Group 1d and Group 2d) showed weakly orange fluorescence (Fig. 8B,D).
Discussion
The results of our study show that Al exposure at both normal and high human dietary level impairs short and 
long term memory and promotes catalepsy. Moreover, our results point out that in addition to oxidative stress and 
cholinergic dysfunction, inflammation though microglia and COX-2 activation is a way by which Al can induce 
toxicity in the hippocampus. The present study has investigated the effects of dietary supplementation with EWH, 
with known antioxidant and anti-inflammatory properties, against Al effects. Our findings suggest that the EWH 
could be used as a functional food ingredient to prevent or minimize Al effects after long-term exposure. Namely, 
EWH prevents cognitive impairments, cholinergic dysfunction and hippocampal oxidative stress and inflamma-
tion induced by Al. The current study shows the specific presence of Al in the hippocampus of Al-exposed rats, 
however further detailed study will be necessary to verify the precise locations of deposits of Al in the brain.
Al is neurotoxic and its toxicity has been demonstrated as the main cause of encephalopathy in renal dialysis 
patients46. Over the past few decades the so-called “aluminum hypothesis” on AD has been debated and investi-
gated through experimental and clinical studies and, now AD is considered as an acute response to chronic intox-
ication by Al8,47. Al toxic effects appear when the Al content of any tissue achieves a toxic threshold or burden47. 
Recently, we have demonstrated that Al exposure at human dietary level reaches a threshold sufficient to promote 
cognitive dysfunction30.
Environmental accidents can expose people to high concentrations of Al48,49. One such accident occurred on 
July 6th 1988 in Camelford, Cornwall, UK when 20 tons of aluminum sulphate was discharged into the mains 
Figure 7. Effect of EWH on hippocampus COX-2 immunoreactivity in Al-treated rats. Immunoreactivity for 
COX-2 (arrows) in hippocampus of controls group (A and D), Al at 8.3 mg/kg b.w. (B) and Al at 100 mg/kg 
b.w. (E), EWH + Al 8.3 (C) and EWH + Al 100 (F) detected by immunohistochemistry. Scale bar 50 µm and 
objective X20. COX-2 score for intensity of immunoreactivity (0 to 4 + scale) (objective X40) of rats treated with 
AlCl3 at 8.3 (G) or 100 (H), co-treated or not with EWH. Results are expressed as mean ± SD, n = 8, *P < 0.05 
compared with their corresponding controls (two-way ANOVA and Bonferroni as post-hoc test).
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water supply. Up to 20 000 people were exposed to concentrations of Al which were 500–3000 times the accept-
able limit under European Union legislation (0.200 mg/L)48. Since that, three follow-up studies were carried out 
reporting severe cognitive decline, unspecified neuropathological features and high brain Al levels from two indi-
viduals who were living in the Camelford area at that time44,50,51. The general population is exposed to Al every 
minute and, due to myriad Al applications and sources, most of them are exposed to Al at a level that exceeds the 
tolerable weekly intake recommended by International Regulatory Agencies4–7. Therefore, strategies worldwide 
that aim to reduce human Al exposure or prevent the effects of this burgeoning and silent poison are needed. The 
current study shows that a functional food ingredient which could be easily introduced in the human diet can 
minimize the cognitive effects of Al exposure by diet.
But how does EWH exerts its effects? EWH is produced after 8 h of hydrolysis digestion with pepsin releasing 
bioactive peptides with in vitro peroxyl radical-scavenging activity (574 μmol Trolox/g protein). Among the iden-
tified peptides, amino acid sequences with Pro, Lys or Arg as a C-terminal residue exhibit ACE inhibitory activity, 
Arg or Tyr at the N-terminal position show vascular-relaxing activity and, finally the presence of Tyr and Phe in 
C-terminal residue is related to scavenging free radicals and antioxidant properties19. In vivo, the EWH improves 
obesity-related complications20,52, cardiovascular53, reproductive22 and neurologic disorders after chronic expo-
sure to metals24 and, these effects were related to its antioxidant and anti-inflammatory capacities. In the present 
study, rats treated with Al and co-treated with EWH did not develop memory and behavior dysfunctions after 
Al exposure, suggesting the efficacy of EWH to counteract the adverse effects after Al exposure at low and high 
levels.
Al is a neurotoxin in which effects could be maximized in individuals that share susceptibility factors, such 
as environmental or genetic traits9. Al3+ is a potent pro-oxidant, its toxicity being strongly related to oxidative 
Figure 8. Effect of EWH on the presence of aluminum (orange) in hippocampus. Representative images of Al 
in the hippocampus: lumogallion fluorescence in rats treated with AlCl3 at 8.3 mg/kg (A) and co-treated with 
EWH (B), lumogallion fluorescence in rats treated with AlCl3 at 100 mg/kg (C) and co-treated with EWH (D). 
DAPI-staining (blue), (A’–D’); lumogallion & DAPI overlay (A”–D”). Arrows indicate the specific presence of 
aluminum. Scale bar: 50 µm (objective X20).
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stress in several organs12,14,17. Furthermore, experimental animals exposed to the adjuvant Al oxyhydroxide 
(Alhydrogel®) or to AlCl3 at low doses showed activation of the innate immune system with increased numbers 
of macrophage and microglia together with high Al levels12,14,54. Here we found that besides oxidative stress and 
cholinergic dysfunction, the presence of Al in the hippocampus promoted microglial activation, which in turn 
appears to induce the inflammatory COX-2 cascade activation. In agreement, we have recently seen that ROS and 
COX-2-derived prostanoids are important mediators of vascular dysfunction after Al exposure12.
In the present study, we demonstrated the capacity of the EWH to counteract the behavioral dysfunction 
induced by Al. Namely, the co-treatment with EWH prevents memory impairment and catalepsy development 
after Al exposure. Among the mechanisms of actions, ours results suggest that the EWH prevents the inhibition 
of cholinergic activity and increased oxidative stress and inflammation. However, there are numerous ways by 
which EWH could be acting to counteract the Al effects, for example acting on the gastrointestinal tract. Besides 
the multiple functionalities of the GI tract, such as absorption of dietary components and immune regulation, 
the gastrointestinal tract is the main and first route of contact with the ingested Al, influencing its bioavailability 
and absorption55. Therefore, it is possible to speculate that EWH effects could originate in this important target 
organ for Al deposition. Moreover, the ameliorative effects of the EWH on cardiometabolic complications in 
Zucker obese rats were related to its action on the gastrointestinal tract21. However, at this moment we are still not 
able to affirm which mechanism (s) is/are responsible for the beneficial effect of the EWH. We should consider 
that both, Al and EWH, are being administered through oral routes which may appoint for two main protective 
mechanisms: 1). EWH can reduce/inhibit the absorption of Al across the GI tract, then reducing the effects of Al 
into the body or, 2). EWH, maybe by its antioxidant and anti-inflammatory properties, can inhibit/prevent the 
consequences of the enhanced human body burden of Al.
Conclusion
Taken as a whole, our data suggest that the EHW could be used as a supplementary dietary ingredient to provide 
a strategy against Al toxicity. Our results show that daily intake of Al at a concentration achieved through the 
human diet impairs short and long term memory and induces catalepsy, effects similar to those found after Al 
exposure at a high level. Moreover, besides oxidative stress and cholinergic dysfunction, our results highlight 
inflammation though microglia and COX-2 as a way by which Al can induce toxicity in the hippocampus. The 
co-treatment with EWH is able to partially prevent the presence and effects of Al in the brain. Therefore, EWH 
could be used as a functional food ingredient to protect against the toxicity of aluminum in the human diet.
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